A single-centre Phase Ib multiple ascending dose clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of IW 2143 (BNC 210) in healthy male volunteers

Trial Profile

A single-centre Phase Ib multiple ascending dose clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of IW 2143 (BNC 210) in healthy male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Anxiety disorders; Depressive disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Sep 2016 Results presented at the 29th Annual Congress of the European College of Neuropsychopharmacology
    • 16 Sep 2015 Status changed from not yet recruiting to completed.
    • 16 Sep 2015 Positive results published in a Bionomics media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top